AKTS
$19.23
Aktis Oncology, Inc.
Recent News
Aktis Oncology Unveils Miniprotein Radiopharma Platform, Highlights Nectin-4 and B7-H3 Programs
Aktis Oncology (NASDAQ:AKTS) executives outlined the company’s strategy to expand the use of targeted radiopharmaceuticals beyond the limited set of currently approved products, emphasizing a novel “miniprotein” targeting approach, internally built supply chain capabilities, and two lead clinical pr
Aktis Oncology Details Radiopharma Expansion, Fast Track Win for AKY-1189 at TD Cowen Conference
Aktis Oncology (NASDAQ:AKTS) used a presentation at TD Cowen’s 46th Annual Healthcare Conference to outline its strategy to broaden the reach of targeted radiopharmaceutical therapy beyond today’s most established targets and to provide updates on its two lead clinical programs and manufacturing and
Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum Rebound
Aktis Oncology (AKTS) is drawing attention after recent share price moves, with a 2.9% gain over the past day and an 11.4% rise over the past week, contrasting with a decline over the past month. See our latest analysis for Aktis Oncology. Looking beyond the latest moves, Aktis Oncology’s 7 day share price return of 11.42% sits alongside a 30 day share price return of 7.62% and a year to date share price return of 10.71%. This suggests that recent momentum may be starting to rebuild after...
Medtronic Diabetes Unit MiniMed Seeks $784 Million in US IPO
The Northridge, California-based firm plans to market 28 million shares for $25 to $28 each, according to its filing Tuesday with the US Securities and Exchange Commission. The IPO is expected to price March 5, an investor presentation shows. At the top end of the price range, MiniMed would have a market value of about $7.86 billion, based on the outstanding shares listed in the filing.
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut
Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.